Acute myeloid leukemia

Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome

Genki Yamato1,2 · Takao Deguchi3 · Kiminori Terui4 · Tsutomu Toki5 · Tomoyuki Watanabe6 · Takahiro Imaizumi6 · Asahito Hama7 · Shotaro Iwamoto8 · Daisuke Hasegawa9 · Takahiro Ueda10 · Tomoko Yokosuka11 · Shiro Tanaka12 · Ryu Yanagisawa13 · Katsuyoshi Koh14 · Akiko M. Saito15 · Keizo Horibe15 · Yasuhide Hayashi16,17 · Souichi Adachi17 · Shuki Mizutan18 · Takashi Taga19 · Etsuro Ito6 · Kenichiro Watanabe20 · Hideki Muramatsu21

Received: 4 October 2020 / Revised: 8 January 2021 / Accepted: 28 January 2021 / Published online: 3 March 2021
© The Author(s) 2021. This article is published with open access

Transient abnormal myelopoiesis (TAM), also known as transient leukemia or transient myeloproliferative disorder, occurs in approximately 5–10% of neonates with Down syndrome (DS) and is characterized by the transient appearance of blast cells with megakaryoblastic and/or erythroblastic characteristics in the peripheral blood [1, 2]. Approximately 20% of TAM cases result in early death and 16–23% of survivors develop acute megakaryoblastic leukemia (AMKL) within 4 years [3–6]. A somatic GATA1 gene mutation is shared by both TAM [7] and AMKL cells [8, 9].

Preceding studies have identified several risk factors associated with early death, including high white blood cell (WBC) count (≥100 × 109/L), preterm delivery (<37 weeks), elevated direct bilirubin (≥5 mg/dL), hepatomegaly, ascites, and bleeding diatheses [3–6]. However, the definite clinical predictive indicators of AMKL onset in patients with TAM remain unclear. Here, we analyzed 167 TAM patients with DS who were enrolled in the TAM-10 prospective observational study conducted by the Japan Pediatric Leukemia/
The details of the eligibility criteria, methods of flow cytometric minimal residual disease (FCM-MRD), GATA1 mutations analysis, meta-analysis of DS-TAM clinical studies, and statistical analysis were described in Supplementary methods (Supplementary Tables 1–3).

The clinical characteristics and laboratory findings of 167 patients with TAM are summarized in Supplementary Table 4. The median (range) value of WBC was 38.3 (2.4–478.7) × 10^9/L. Of the 167 patients, somatic GATA1 gene mutations were confirmed in 163 (98%) patients (10 identified by next-generation sequencing [NGS] only). Patients with GATA1 mutations identified only using NGS had significantly lower WBC counts (P < 0.001) and blast percentage (P < 0.001) than those with GATA1 mutations identified by Sanger sequencing at diagnosis (data not shown). GATA1 mutations were divided into high or low expression types according to the definition of a previous report (Supplementary Fig. 1) [10]. Details and expression type of GATA1 mutations are described in Supplementary Table 5. FCM-MRD positivity (cutoff level, ≥ 0.1%) was detected at 1 and 3 months in 107 of 133 (80%) and 20 of 104 (19%) patients, respectively.

Sixty-eight of the 167 (41%) patients received some therapeutic interventions, including low dose cytarabine (LDAC) (n = 52), exchange blood transfusion (ET) (n = 20), and systemic steroid therapy (n = 30). The LDAC dose ranged from 1.0 to 1.5 mg/kg/day, and the median duration of treatment was 6 days (Supplementary Table 6). Details of systemic steroid therapy in 30 patients with TAM are summarized in Supplementary Tables 7 and 8. High-grade adverse events (grades 3 and 4) according to the CTCAE version 3.0 occurred in 52 patients who received LDAC and were described in Supplementary Table 9. High-frequency adverse events from LDAC therapy included neutropenia (65%), anemia (56%), thrombocytopenia (65%), and elevated blood bilirubin (56%). However, no patients died from adverse events with LDAC therapy.

The 4-year OS and EFS were 81% (95% confidence interval [CI]; 74.2–86.3%) and 65% (95% CI; 57.3–71.9%), respectively (Fig. 1A, B). Thirty-one of the 167 patients (19%) died, and their causes of death were described in Supplementary Table 10. Of these, early death (<9 months of age) occurred in 22 of 167 (13%) patients. Among the 138 patients without death events, 28 (20%) developed AMKL. The CI rate (CIR) of early death at 9 months was 17.6% (95% CI; 12.2–23.8%) and the rate of leukemia development at 4 years was 17.3% (95% CI; 11.9–23.5%) (Fig. 1C, D).

Univariable and multivariable analysis of the risk factors for early death are shown in Supplementary Table 11. The multivariable analysis identified the following independent risk factors for early death: a high WBC count (P = 0.002), systemic edema (P < 0.001), low birth weight (P = 0.037), systemic steroid therapy (P = 0.007), and elevated direct bilirubin (P = 0.007).

Leukemia development was significantly associated with FCM-MRD positivity at 1 month (P = 0.022) and 3 months (P = 0.002) (Fig. 1E, F). Furthermore, systemic steroid therapy was inversely associated with leukemia development (P = 0.008) (Supplementary Fig. 2), although 50% (15 of 30) of patients who received systemic steroid therapy died before leukemia development, reflecting their severe clinical conditions.

Univariable and multivariable analyses of the risk factors for leukemia development are shown in Supplementary Table 12. The multivariable analysis demonstrated that the positivity of FCM-MRD at 3 months and systemic steroid therapy were independent predictive factors for leukemia development.

In the subgroup of 36 patients with a high WBC count (≥100 × 10^9/L), LDAC therapy significantly improved survival (P = 0.017) (Fig. 2A). However, there was no significant difference in the CIR of early death between patients with or without other therapeutic interventions, including ET or systemic steroid therapy (Supplementary Fig. 3).

We performed a meta-analysis of the current study and five previously reported cohorts of TAMs (Supplementary Table 13) [3–6, 11]. We compared WBC counts, the rate of early death, the CI of leukemia development, and the rate of interventions, including LDAC, ET, and systemic steroid therapy. Remarkably, the rate of LDAC intervention was adversely associated with the early death rate according to the Cochran-Armitage test for trend (P = 0.002, Fig. 2B). The cohorts without LDAC intervention [5, 6] reported higher early death rates; conversely, the cohorts with a higher percentage of LDAC intervention rates (31–38%) [11] (this study) reported lower early death rates. Meanwhile, there was no significant difference or trend in leukemia development among these cohorts.

TAM patients with life-threatening symptoms should be treated with LDAC [3, 4, 11, 12]. In this TAM-10 study, LDAC therapy significantly reduced the early death rates for patients with a high WBC count (≥100 × 10^9/L) who are considered to be severe TAM patients (Fig. 2A). Furthermore, we confirmed the high safety profile of LDAC treatment and noted that no patients died of adverse events from LDAC therapy (Supplementary Table 9). These safety
assessment results will allow us to safely broaden the threshold for LDAC intervention.

Meanwhile, the meta-analysis of this TAM-10 study and the other five reported large TAM cohorts (>40 cases) [3–6, 11] identified a significant trend between a higher rate of LDAC intervention and the reduction of early death rates (Fig. 2B). In particular, Flasinski et al. reported the highest rate of patients receiving therapeutic LDAC interventions (38%) and achieved a very low early death rate of 5%. In the TAM-10 study, we reported the second-highest rate of patients receiving therapeutic LDAC interventions (31%) and achieved the second-lowest early death rate (13%). These results suggest that LDAC therapy is an indispensable therapy for at least severe TAM patients, and more patients might be eligible for this treatment than previously considered.

Consistent with previous studies [3, 11], no clinical parameters predicted leukemia development in this study. However, we determined that FCM-MRD positivity at 3 months was a significant predictive indicator for leukemia development in the TAM-10 study cohort. Flasinski et al. also reported that being MRD-positive at week 12 was significantly associated with AMKL development [11]. These observations demonstrate the importance of FCM-MRD positivity for the prediction of leukemia development in patients with TAM. In this TAM-10 study, the FCM-
MRD positivity cutoff value was set at 0.1%, but more sensitive MRD analyses can be achieved by using error-corrected NGS [13]. The clinical significance of NGS-MRD for TAM patients should be clarified in future studies.

Flasinski et al. reported that MRD-guided LDAC therapy for patients who were MRD-positive at eight and ten weeks failed to prevent AMKL development [11]. In this TAM-10 study, there was no significant difference in the incidence of AMKL between patients who had or had not been treated with LDAC; conversely, systemic steroid therapy showed a significant protective effect for leukemia development in the multivariable analysis (P < 0.001). An in vitro drug sensitivity test of 41 drug panels showed that the peripheral blood mononuclear cells (PBMCs) of five patients with TAM showed a higher sensitivity to cytarabine, trametinib, and dexamethasone than the PBMCs of healthy volunteers [14]. These results suggest that steroids may be a candidate for AMKL prophylactic intervention in patients with TAM. However, only 15 patients who were administered steroid therapy and survived were analyzed; therefore, well-designed clinical research studies need to be conducted on this subject in future.

Limitations of this study include the fact that the TAM-10 study was a prospective observational study, and the dose and duration of LDAC therapy were not uniform. Furthermore, the patients enrolled in the TAM-10 study had a higher frequency of congenital heart malformations (67%) and higher WBC counts than in a previous population-based DS registry study [15]. This study may have a cohort bias, owing to the inclusion of more symptomatic cases.

In summary, this TAM-10 study revealed that LDAC intervention is an indispensable therapy for reducing the early death rate and FCM-MRD is a useful marker for leukemia development in patients with TAM. Furthermore, systemic steroid therapy might suppress leukemia development. These results provide useful information for the design of future clinical studies to improve early mortality and AMKL incidence in patients with TAM.

Acknowledgements We pay special tribute to and acknowledge the significant contributions of Akira Kikuchi to this article. He continually challenged our premises and kept us on task throughout the entire process. The authors would also like to thank Enago (https://www.enago.jp) for the English language review. This work was supported by Health and Labor Sciences Research Grants (201128038B and 201324122 A) and the Japan Agency for Medical Research and Development (AMED) (Innovative Cancer Medical Practice Research Project, 18ck0106435h0001).

Author contributions GY performed the research, analyzed the data, and wrote the paper. HM designed and performed the research, led the project, and wrote the paper. TD performed the flow cytometric analysis and minimal residual disease measurements. KT, TTo and EI performed the GATA1 mutation analysis. TI and TW performed the research and bioinformatics analysis. AH performed the central morphology review of the peripheral blood smears. SL, DH, TU, TY, ST, RY, KK, AS, KH, YH, SA, SM and TTa collected clinical samples and data and performed the research. KW designed and performed the research and led the project. All authors critically reviewed and revised the manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References

1. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr. 2005;217:126–34.

2. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110:2128–31.

3. Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood. 2011;118:6752–9.

4. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111:2991–8.

5. Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW, et al. Children’s Oncology Group (COG). A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood. 2006;107:4606–13.

6. Muramatsu H, Kato K, Watanabe N, Matsumoto K, Nakamura T, Horikoshi Y, et al. Risk factors for early death in neonates with Down syndrome and transient leukaemia. Br J Haematol. 2008;142:610–5.

7. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298–300.

8. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–52.

9. Alford KA, Reinhardt K, Garnett C, Norton A, Böhmer K, von Neuhoff C, et al. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood. 2011;118:2222–38.

10. Kanezaki R, Toki T, Terui K, Xu G, Wang R, Shimada A, et al. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood. 2010;116:4631–8.

11. Flasinski M, Scheibke K, Zimmermann M, Creutzig U, Reinhardt K, Verwer F, et al. Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study. Blood Adv. 2018;2:1532–40.

12. Tunstall O, Bhatnagar N, James B, Wright M. British Society for Haematology. Guidelines for the investigation and management of transient leukaemia of down syndrome. Br J Haematol. 2018;182:200–11.

13. Balagopal V, Hantel A, Kadri S, Steinhardt G, Zhen CJ, Kang W, et al. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS ONE. 2019;14:e0224097.

14. Yokosuka T, Sakurai Y, Miyagawa N, Keino D, Iwasaki F, Hamanoue S, et al. In vitro testing of trametinib in transient abnormal myelopoiesis [abstract]. Pediatr Blood Cancer. 2019;66:S35–36.

15. Roberts I, Alford K, Hall G, Juban G, Richmond H, Norton A, et al. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood. 2013;122:3908–17.